每年长高超10厘米!诺和诺德长效生长激素已递交监管申请;1.25亿美元助力老花眼眼药水开发

药明康德
May 13, 2025

只需每周一次,诺和诺德长效疗法达到3期临床主要终点诺和诺德(Novo Nordisk)今日公布了篮式3期临床试验REAL8的积极数据,结果显示每周一次使用Sogroya(somapacitan)在改善小于胎龄儿(SGA)、努南综合征(NS)或特发性矮小(ISS)患儿的青春期前年生长速率方面,与每日一次使用的生长激素Norditropin(somatropin)相比,达到非劣效性标准。此外,在NS...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10